Abstract: The invention relates to a method of obtaining a composition comprising allolactose by a applying one or more glucose-deficient lactic acid bacteria strains. The invention also relates to the use of said strains for the preparation of a food product comprising allolactose and to the use of said strains for increasing the content of allolactose in a food product. The invention also relates to a food product comprising allolactose and one or more glucose-deficient lactic acid bacteria strains.
Type:
Application
Filed:
February 22, 2022
Publication date:
August 29, 2024
Applicant:
Chr. Hansen A/S
Inventors:
Vojislav VOJINOVIC, Kim Ib SOERENSEN, Laurent GUINOT
Abstract: The present invention provides evidence that administration of a probiotic product to newborn piglets and during suckling makes the piglets more resilient towards an ETEC challenge post-weaning and after cessation of the probiotic administration. The pigs administered with probiotics pre-weaning were faster at overcoming the ETEC infection by which ETEC counts in feces were significantly faster reduced compared with non-probiotic supplemented pigs.
Abstract: Fucosyltransferases capable of transferring a fucose residue from a donor substrate to a lactotetraose, methods for producing fucosylated oligosaccharides utilizing the fucosyltransferases, and the use of the thus produced fucosylated oligosaccharides for manufacturing nutritional compositions are provided.
Abstract: The present invention relates to a method for producing a fermented milk product (e.g. a pasta filata cheese) with a relatively stable pH value at the end of the fermentation comprising use of lactase in a first step (a) and lactic acid bacteria (LAB) in a further step, characterized by that the LAB are lactose-deficient (Lac(?)) and capable of metabolizing glucose (Glu(+)). The invention further relates to a Streptococcus thermophilus cell CHCC26980 deposited with registration number DSM32600 and a method to obtain a mutant of this strain.
Type:
Application
Filed:
June 10, 2022
Publication date:
August 1, 2024
Applicant:
Chr. Hansen A/S
Inventors:
Michael Mitsuo Saito, Véronique Jactat, Thomas Janzen, Mikkel Hviid Danielsen Hornnes
Abstract: The present invention is in the field of dairy technology. It relates to a method for producing a fermented milk product comprising the steps: (a) Providing a starter culture comprising one or more lactic acid bacteria strains selected from a group consisting of: DSM 22935, DSM 22585, DSM 22586, DSM28910 and DSM33677; (b) Adding the starter culture to a milk base to ferment said milk base until a target pH is reached; and (c) Adding a lactase to the milk base; wherein the fermented milk product has improved texture and/or reduced post-acidification as compared to a fermented milk product produced without addition of the lactase of step c) or the starter culture of step a).
Type:
Application
Filed:
May 5, 2022
Publication date:
July 18, 2024
Applicant:
Chr. Hansen A/S
Inventors:
Victoria Prebner, Vojislav Vojinovic, Maria Elina Sundberg
Abstract: A method for producing a cheese with reduced amount of galactose comprising inoculating milk with Streptococcus thermophilus Gal(+) bacteria and Lactobacillus Gal(+) Lac(?) bacteria.
Type:
Grant
Filed:
June 20, 2019
Date of Patent:
July 16, 2024
Assignee:
Chr. Hansen A/S
Inventors:
Thomas Janzen, Ditte Ellegaard Christiansen, Veronique Jactat, Kasper Rosenkvist, Charlotte Elisabeth Grüner Schöller
Abstract: The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.
Abstract: The present invention relates to a composition comprising one or more novel Streptococcus thermophilus strain(s), and the use of said composition for producing a fermented product such as a dairy product with e.g. an increased sweetness. The invention also relates to novel Streptococcus thermophilus strain(s) as such.
Type:
Application
Filed:
February 23, 2022
Publication date:
July 11, 2024
Applicant:
Chr. Hansen A/S
Inventors:
Jesper BROEND, Sonja BLOCH, Kim Ib SOERENSEN
Abstract: Disclosed is a process for the production of a desired oligosaccharide, the process comprises providing a genetically engineered microbial cell which possesses a saccharide importer for the uptake of an intermediate oligosaccharide, and an enzyme being able to convert the intermediated oligosaccharide by transferring a monosaccharide moiety from a donor substrate to the intermediate oligosaccharide; cultivating the genetically engineered microbial cell in the presence of an intermediate oligosaccharide to generate the desired oligosaccharide; and retrieving the desired oligosaccharide.
Abstract: The present invention relates to the field of frozen or dry compositions for prokaryotes, in particular fermentative bacteria such as lactic acid bacteria, a method for preparing frozen or dry prokaryotic compositions and compositions which may be prepared by said method. The cells in a cell concentrate are activated by allowing them to ferment a carbohydrate, before freezing and/or drying to provide a product. The hydrophobicity of the cell surface increases during activation, and this has been found to increase the storage stability of the product.
Type:
Application
Filed:
November 29, 2021
Publication date:
July 11, 2024
Applicant:
Chr. Hansen A/S
Inventors:
Zuzana Mladenovska, Surender Kumar Dhayal, Kim Nielsen
Abstract: The present invention relates to a composition for inhibiting biofilm comprising at least one selected from the group consisting of Lactobacillus rhamnosus, its culture medium, its extract and its cell-free supernatant and collagen hydrolysate. Although Lactobacillus rhamnosus can inhibit biofilm formation even as a single agent, the inhibitory ability is significantly increased when it is simultaneously treated with the collagen hydrolysate. The collagen hydrolysate inhibits acid production of Lactobacillus rhamnosus or Streptococcus mutans. Thus, the Lactobacillus rhamnosus and collagen hydrolysate can be usefully used as a composition for inhibiting the production of biofilms, in particular biofilms occurring in the oral cavity and a composition for preventing, alleviating, or treating oral diseases caused by the biofilms.
Type:
Application
Filed:
April 4, 2022
Publication date:
July 4, 2024
Applicants:
VIXXOL Corporation, Chr. Hansen A/S
Inventors:
Sung Chul Yoo, Seon Hwa Kim, Dong Yeop Kim
Abstract: Disclosed is a method for purifying sialylated oligosaccharides from a fermentation broth, cell-lysate or biocatalytic reaction mixture for obtaining high amounts of desired sialylated oligosaccharides in high purity. The method is particular suitable for the large-scale economic purification of sialylated human milk oligosaccharides (such as 3?-sialyllactose, 6?-sialyllactose or sialylated lacto-N-tetraose derivatives) from microbial fermentation, using recombinant bacterial cells or yeast cells. The obtained material is of high purity and can be used for food or medical application such like medical nutrition products, infant formula, dietary supplements, general nutrition products (e.g. dairy drinks).
Type:
Application
Filed:
January 19, 2024
Publication date:
June 20, 2024
Applicant:
Chr. Hansen HMO GmbH
Inventors:
Stefan JENNEWEIN, Markus HELFRICH, Benedikt ENGELS
Abstract: The present invention relates to a method for producing fucosylated oligosaccharides by using a recombinant prokaryotic host cell that is cultivated on a gluconeogenic substrate, as well as to the host cell and its use. The host cell is genetically modified in that the activity of a fructose-6-phosphate converting enzyme is abolished or lowered, and the transport of the produced fucosylated oligosaccharide through the cell membrane is facilitated by an exogenous transport protein.
Type:
Application
Filed:
December 21, 2023
Publication date:
June 20, 2024
Applicant:
Chr. Hansen HMO GmbH
Inventors:
Stefan Jennewein, Dirk Wartenberg, Katja Parschat
Abstract: The present invention provides a pharmaceutical composition comprising a probiotic and a prebiotic for preventing acquisition of and/or alleviating symptoms associated with an infection caused by an Extended-spectrum beta-lactamases (ESBL) producing organism and other drug resistant pathogens. More particularly, the pharmaceutical composition comprises at least one Lactillobacillus specie(s) as a probiotic and at least one oligosaccharide as a prebiotic. The present invention further provides a method of preventing acquisition of and/or treating an infection caused by Extended-spectrum beta-lactamases (ESBL) producing bacteria and other drug resistant pathogens, comprising administering an effective amount of a pharmaceutical composition comprising a probiotic and a prebiotic to a subject in need thereof.
Abstract: The present invention is related to the field of reddening of food products. In particular the present invention relates to the preservation or optimization of nitrate reductase activity of frozen and/or dried lactic acid bacteria cultures or Micrococcaceae cultures (particularly cultures comprising one or more species of Staphylococcus having nitrate reductase activity).
Type:
Grant
Filed:
May 3, 2019
Date of Patent:
June 11, 2024
Assignee:
Chr. Hansen A/S
Inventors:
Tina Malling Thorsen, George Nabin Baroi, Robin Taponen, Jakob Soeltoft-Jensen, Birgitte Yde
Abstract: The present invention relates to a process for producing a fermented milk soft cheese product including the steps of a) Providing a first milk base, b) Optionally subjecting the first milk base to a concentration step to obtain a concentrated first milk base, c) Adding a first starter culture including at least one EPS producing lactic acid bacterium strain, d) Fermenting the concentrated first milk base for a period of time until a target pH is reached to obtain an EPS-containing fermented milk composition, e) Mixing the EPS-containing fermented milk composition with one or more other ingredients, if any, selected from the group consisting of a milk fat composition, a second fermented milk composition and one or more additives, to obtain a fermented milk mixture, and f) Subjecting the fermented milk mixture to heat treatment to obtain a fermented milk soft cheese product.
Type:
Grant
Filed:
August 6, 2019
Date of Patent:
May 28, 2024
Assignee:
Chr. Hansen A/S
Inventors:
Jean-Marie Odinot, Emilien Langevin, Luciana Jimenez, Kasui Tang, Vera Kuzina Poulsen, Elahe Ghanei Moghadam, Gunnar Oeregaard
Abstract: The present invention relates to a novel Streptococcus thermophilus strain having improved texturizing properties, compositions comprising said strain as well as fermented products manufactured using said strain.
Type:
Application
Filed:
January 6, 2022
Publication date:
May 23, 2024
Applicant:
Chr. Hansen A/S
Inventors:
Thomas Janzen, Ditte Christiansen, Jesper Broend, Victoria Prebner, Ilenia Manuguerra, Geoffrey Ras
Abstract: The present invention relates to the use of one or more glycosidases in the process for the production and/or purification of a produced desired oligosaccharide. The process is preferably a microbial fermentation process using a host microorganism, which may also comprise nucleic acids expressing sugar catabolic pathway proteins suitable for the degradation of saccharides otherwise hindering the purification of the desired oligosaccharide.
Abstract: Microbial starter cultures. More specifically, a method for preparing a microbial culture such as a lactic acid bacteria (LAB) starter culture wherein at least one microbial strain such as a lactic acid bacteria and at least one inactivated yeast strain is inoculated in a culture medium.
Type:
Grant
Filed:
December 10, 2020
Date of Patent:
May 14, 2024
Assignee:
Chr. Hansen A/S
Inventors:
Neda Faraghiparapari, Marie Penderup Jensen, Jakub Kovacs, Anisha Goel
Abstract: The present invention relates to microencapsulated microbial cultures with high storage stability and methods for producing these. In particular, the present invention relates to microbial cultures formulated at high ratios of encapsulation matrix material to core material.